The end of the line is looming for Oxurion, after a clinical trial of its last pipeline drug for diabetic macular oedema (DME) failed to meet its primary endpoint. With its cash reserves dwindling ...

Lab-on-a-chip articles from across Nature Portfolio A lab-on-a-chip is a class of device that integrates and automates multiple laboratory techniques into a system that fits on a chip up to a ...